Listen
Reason for request
Reassessment of the Actual Benefit of all medicines indicated in hormone replacement therapy for the menopause at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code
-
Clinical Benefit
| Substantial |
The actual benefit of the proprietary medicinal products LUTENYL remains substantial in the indication “in postmenopausal women, artificial cycles in combination with an oestrogen” and that of LUTENYL 3.75 mg remains substantial in the indication “in combination with an oestrogen within the framework of hormone replacement therapy (HRT) in non-hysterectomised postmenopausal women” in non-hysterectomised postmenopausal women and within the limits defined for the use of the oestrogen treatment with which it is combined when the proprietary medicinal products are used in accordance with the recommendations of the Committee.
|
Therapeutic use
- |
-
